ORCID: https://orcid.org/0000-0003-2873-8667; Dombi, Zsófia B. 
ORCID: https://orcid.org/0000-0002-0390-4852; Acsai, Károly; Barabássy, Ágota; Schmitt, Andrea 
ORCID: https://orcid.org/0000-0002-5426-4023 und Németh, György
  
(Februar 2023):
		The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials.
	
	 In: CNS Spectrums, Bd. 28, Nr.  1: S. 104-111
	
      
        
          
             [PDF, 602kB]
          
        
      
![the-efficacy-and-safety-of-cariprazine-in-the-early-and-late-stage-of-schizophrenia-a-post-hoc-analysis-of-three-randomized-placebo-controlled-trials.pdf [thumbnail of the-efficacy-and-safety-of-cariprazine-in-the-early-and-late-stage-of-schizophrenia-a-post-hoc-analysis-of-three-randomized-placebo-controlled-trials.pdf]](https://epub.ub.uni-muenchen.de/style/images/fileicons/application_pdf.png) Creative Commons: Namensnennung 4.0 (CC-BY)
            
        	  
	
  Creative Commons: Namensnennung 4.0 (CC-BY)
 
			  
			  
               
              
  
              Abstract
Background: The aim of the post hoc analysis was to better understand the efficacy and safety of cariprazine in patients with schizophrenia for less than 5 years (early stage) and for more than 15 years (late stage).
Methods: Data from three phase II/III randomized, double-blind, placebo-controlled trials with similar design in patients with acute exacerbation of schizophrenia were pooled and patients with early and late stage of schizophrenia were determined. A mixed-effects model for repeated measures approach was applied and least square (LS) mean changes from baseline to week 6 on the Positive and Negative Syndrome Scale (PANSS) total and factor scores were reported. Descriptive statistics were used for safety analyses including treatment emergent adverse events (TEAEs) and discontinuation rates.
Results: Overall, 460 patients were identified as being in the early and 414 in the late stage of schizophrenia. The pooled analysis evaluating mean change from baseline to week 6 in the PANSS total score indicated statistically significant difference between cariprazine and placebo in favor of cariprazine in both the early (LS mean difference [LSMD] −7.5 P < .001) and late stage (LSMD −6.7, P < .01) subpopulation. Early stage patients experienced similar amount of TEAEs (CAR 67.3%, PBO 54.1%) as patients in the late stage (CAR 69.6%, PBO 65.6%).
Conclusion: In conclusion, cariprazine, a potent D3-D2 partial agonist has been found to be safe and effective in the treatment of early and late stage schizophrenia.
| Dokumententyp: | Zeitschriftenartikel | 
|---|---|
| Fakultät: | Medizin > Klinikum der LMU München > Klinik und Poliklink für Psychiatrie und Psychotherapie | 
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit | 
| URN: | urn:nbn:de:bvb:19-epub-128948-7 | 
| ISSN: | 1092-8529 | 
| Sprache: | Englisch | 
| Dokumenten ID: | 128948 | 
| Datum der Veröffentlichung auf Open Access LMU: | 29. Okt. 2025 14:49 | 
| Letzte Änderungen: | 29. Okt. 2025 14:49 | 
 
		 
	 
    


